Skip to main content
Erschienen in: Annals of Hematology 4/2012

01.04.2012 | Original Article

Evaluation of circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to predict risk profile, response to antimicrobial therapy, and development of complications in patients with chemotherapy-associated febrile neutropenia: a pilot study

verfasst von: L. Kwofie, B. L. Rapoport, H. Fickl, P. W. A. Meyer, P. Rheeder, H. Hlope, R. Anderson, G. R. Tintinger

Erschienen in: Annals of Hematology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) is a useful marker of infection in patients with sepsis, but has not been adequately evaluated in patients with chemotherapy-associated febrile neutropenia (FN). The value of sTREM-1 in this setting has been tested in a retrospective, pilot study using stored serum from 48 cancer patients with documented FN. On presentation, patients were categorized according to the Talcott risk-index clinical score. Circulating soluble sTREM-1 was measured using an ELISA procedure, while procalcitonin (PCT) or interleukins 6 (IL-6) and 8 (IL-8), included for comparison, were measured using an immunoluminescence-based assay and Bio-Plex® suspension bead array system, respectively. Circulating concentrations of both sTREM-1 and PCT were significantly (P < 0.05) elevated in patients at high risk for complications or death, as predicted by the Talcott score and were significantly lower in patients who responded to empiric antimicrobial agents. Neither IL-6 nor IL-8 accurately predicted serious complications in patients with FN. These observations, albeit from a pilot study, demonstrate that sTREM-1 is indeed elevated in high-risk patients with FN and is potentially useful to predict their clinical course, either together with, or as an alternative to PCT.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266PubMedCrossRef Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266PubMedCrossRef
2.
Zurück zum Zitat Talcott JA, Finberg R, Mayer RJ et al (1988) The medical course of cancer patients with fever and neutropenia. Arch Int Med 148:2561–2568CrossRef Talcott JA, Finberg R, Mayer RJ et al (1988) The medical course of cancer patients with fever and neutropenia. Arch Int Med 148:2561–2568CrossRef
3.
Zurück zum Zitat Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott JA (2000) The multinational association for supportive care in cancer risk-index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott JA (2000) The multinational association for supportive care in cancer risk-index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed
4.
Zurück zum Zitat Nakagawa Y, Suzuki K, Masaoka T (2009) Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy. J Infect Chemother 15:174–179PubMedCrossRef Nakagawa Y, Suzuki K, Masaoka T (2009) Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy. J Infect Chemother 15:174–179PubMedCrossRef
5.
Zurück zum Zitat Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K (2008) The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 36:396–407PubMedCrossRef Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K (2008) The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 36:396–407PubMedCrossRef
6.
Zurück zum Zitat Jimeno A, Garcia-Velasso A, del Val O, González-Billalabeitia E, Hernando S, Hernández R, Sánchez-Muňoz A, López-Martin A, Durán I, Robles L, Cortes-Funes H, Paz-Ares L (2004) Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 100:2462–2469PubMedCrossRef Jimeno A, Garcia-Velasso A, del Val O, González-Billalabeitia E, Hernando S, Hernández R, Sánchez-Muňoz A, López-Martin A, Durán I, Robles L, Cortes-Funes H, Paz-Ares L (2004) Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 100:2462–2469PubMedCrossRef
7.
Zurück zum Zitat Uys A, Rapoport BL, Fickl H, Meyer PWA, Anderson R (2007) Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1β, -6, -8 and -10. Eur J Cancer Care 16:475–483CrossRef Uys A, Rapoport BL, Fickl H, Meyer PWA, Anderson R (2007) Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1β, -6, -8 and -10. Eur J Cancer Care 16:475–483CrossRef
8.
Zurück zum Zitat Persson L, Söderquist B, Engervall P, Vikerfors T, Hansson L-O, Tidefelt U (2005) Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol 74:297–303PubMedCrossRef Persson L, Söderquist B, Engervall P, Vikerfors T, Hansson L-O, Tidefelt U (2005) Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol 74:297–303PubMedCrossRef
9.
Zurück zum Zitat Massaro KSR, Costa SF, Leone C, Chamone DAF (2007) Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis 7:137. doi:10,1186/1471-2334-7-137 PubMedCrossRef Massaro KSR, Costa SF, Leone C, Chamone DAF (2007) Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis 7:137. doi:10,1186/​1471-2334-7-137 PubMedCrossRef
10.
Zurück zum Zitat Prat C, Sancho JM, Dominguez J, Xicoy B, Giminez m, Ferra C, Blanco S, Lacoma A, Ribera JM, Aurina V (2008) Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 49:1752–1761PubMedCrossRef Prat C, Sancho JM, Dominguez J, Xicoy B, Giminez m, Ferra C, Blanco S, Lacoma A, Ribera JM, Aurina V (2008) Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 49:1752–1761PubMedCrossRef
11.
Zurück zum Zitat Semeraro M, Thomée C, Rolland E, Le Deley MC, Rosselini D, Troalen F, Amoroso L, Drubel M, Hartmann O (2010) A predictor of unfavourable outcome in neutropenic paediatric patients presenting with fever of unknown origin. Pediatr Blood Cancer 54:284–290PubMed Semeraro M, Thomée C, Rolland E, Le Deley MC, Rosselini D, Troalen F, Amoroso L, Drubel M, Hartmann O (2010) A predictor of unfavourable outcome in neutropenic paediatric patients presenting with fever of unknown origin. Pediatr Blood Cancer 54:284–290PubMed
12.
Zurück zum Zitat Schultz MJ, Determann RM (2008) PCT and sTREM-1: the markers of infection in critically-ill patients? Med Sci Monit 14:RA241–RA247PubMed Schultz MJ, Determann RM (2008) PCT and sTREM-1: the markers of infection in critically-ill patients? Med Sci Monit 14:RA241–RA247PubMed
13.
Zurück zum Zitat Ford JW, McVicar DW (2009) TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 21:1–9CrossRef Ford JW, McVicar DW (2009) TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 21:1–9CrossRef
14.
Zurück zum Zitat Jiyong J, Tiancha H, Wei C, Huahao S (2009) Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in bacterial infection: a meta-analysis. Intensive Care Med 35:587–595PubMedCrossRef Jiyong J, Tiancha H, Wei C, Huahao S (2009) Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in bacterial infection: a meta-analysis. Intensive Care Med 35:587–595PubMedCrossRef
15.
Zurück zum Zitat Tejera A, Santolaria F, Diez M-L, Alemán-Valls M-R, Gonzáles-Reimers E, Martínez-Riera A, Milena-Abril A (2007) Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine 38:117–123PubMedCrossRef Tejera A, Santolaria F, Diez M-L, Alemán-Valls M-R, Gonzáles-Reimers E, Martínez-Riera A, Milena-Abril A (2007) Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine 38:117–123PubMedCrossRef
16.
Zurück zum Zitat Lin CH, Ho CC, Yao M, Hsu SC, Yu CJ (2009) sTREM-1 (soluble triggering receptor expressed on myeloid cells-1) as marker indicating infection in patients with neutropenic fever. Am J Respir Crit Care Med 179:A4704 Lin CH, Ho CC, Yao M, Hsu SC, Yu CJ (2009) sTREM-1 (soluble triggering receptor expressed on myeloid cells-1) as marker indicating infection in patients with neutropenic fever. Am J Respir Crit Care Med 179:A4704
17.
Zurück zum Zitat Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer risk-index score. Support Care Cancer 12:555–560PubMedCrossRef Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer risk-index score. Support Care Cancer 12:555–560PubMedCrossRef
18.
Zurück zum Zitat Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P et al (2004) Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicenter study. Clin Microbiol Infect 10:628–633PubMedCrossRef Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P et al (2004) Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicenter study. Clin Microbiol Infect 10:628–633PubMedCrossRef
19.
Zurück zum Zitat Stryjewski GR, Nylen ES, Bell MJ et al (2005) Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med 6:129–135PubMedCrossRef Stryjewski GR, Nylen ES, Bell MJ et al (2005) Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med 6:129–135PubMedCrossRef
20.
Zurück zum Zitat Porfyridis I, Plachouras D, Karagianni V, Kotanidou A, Papiris SA, Giamarellou H, Giamarellos-Bourboulis EJ (2010) Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. BMC Infect Dis 10:286–295PubMedCrossRef Porfyridis I, Plachouras D, Karagianni V, Kotanidou A, Papiris SA, Giamarellou H, Giamarellos-Bourboulis EJ (2010) Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. BMC Infect Dis 10:286–295PubMedCrossRef
21.
Zurück zum Zitat Talcott JA, Whalen A, Clark J et al (1994) Home antibiotic therapy for low risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107–114PubMed Talcott JA, Whalen A, Clark J et al (1994) Home antibiotic therapy for low risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107–114PubMed
22.
Zurück zum Zitat Lav RC, King SM, Richardson SE (1994) Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Pediatr Hematol Oncol 11:417–421CrossRef Lav RC, King SM, Richardson SE (1994) Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Pediatr Hematol Oncol 11:417–421CrossRef
23.
Zurück zum Zitat Talcott JA, Siegel RD, Finberg R et al (1992) Risk assessment in cancer patients with fever and neutropenia. A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMed Talcott JA, Siegel RD, Finberg R et al (1992) Risk assessment in cancer patients with fever and neutropenia. A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMed
24.
Zurück zum Zitat Han YY, Doughty LA, Kofos D, Sasser H, Carcillo JA (2003) Procalcitonin is persistently increased among children with poor outcome from bacterial sepsis. Pediatr Crit Care Med 4:21–25PubMedCrossRef Han YY, Doughty LA, Kofos D, Sasser H, Carcillo JA (2003) Procalcitonin is persistently increased among children with poor outcome from bacterial sepsis. Pediatr Crit Care Med 4:21–25PubMedCrossRef
25.
Zurück zum Zitat Sarmati L, Beltrame A, Dori L, Maffongelli G, Cudillo L, De Angelis G, Picardi A, Ottaviani L, Cefalo MG, Venditti A, Amadori S, Arcese W, Andreoni M (2010) Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis. Am J Hematol 85(5):380–383PubMed Sarmati L, Beltrame A, Dori L, Maffongelli G, Cudillo L, De Angelis G, Picardi A, Ottaviani L, Cefalo MG, Venditti A, Amadori S, Arcese W, Andreoni M (2010) Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis. Am J Hematol 85(5):380–383PubMed
26.
27.
Zurück zum Zitat Yamamura M, Uyemura K, Deans RJ et al (1991) Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254:277–279PubMedCrossRef Yamamura M, Uyemura K, Deans RJ et al (1991) Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254:277–279PubMedCrossRef
28.
Zurück zum Zitat Hakim H, Flynn PM, Srivastava DK, Knapp KM, Li C, Okuma J, Gaur AH (2010) Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 29:53–59PubMedCrossRef Hakim H, Flynn PM, Srivastava DK, Knapp KM, Li C, Okuma J, Gaur AH (2010) Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 29:53–59PubMedCrossRef
29.
Zurück zum Zitat Karapanagiotou EM, Pelekanou E, Charpidou A et al (2008) Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies. Anticancer Res 28:1411–1416PubMed Karapanagiotou EM, Pelekanou E, Charpidou A et al (2008) Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies. Anticancer Res 28:1411–1416PubMed
Metadaten
Titel
Evaluation of circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to predict risk profile, response to antimicrobial therapy, and development of complications in patients with chemotherapy-associated febrile neutropenia: a pilot study
verfasst von
L. Kwofie
B. L. Rapoport
H. Fickl
P. W. A. Meyer
P. Rheeder
H. Hlope
R. Anderson
G. R. Tintinger
Publikationsdatum
01.04.2012
Verlag
Springer-Verlag
Erschienen in
Annals of Hematology / Ausgabe 4/2012
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-011-1339-4

Weitere Artikel der Ausgabe 4/2012

Annals of Hematology 4/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.